EUVIMEDEUVIMED entdecken
Crossref

Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction

Nicolas Hulscher, Harvey Risch, MD, PhD, James A. Thorp, MD, Drew Pinsky, MD, Peter Gillooly, MSc, Kelly Victory, MD und 3 weitere

Medical Research Archives · 2026

DOI: 10.18103/mra.2026.0765 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Nicolas Hulscher und 14 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nattokinase (NK) is an orally administered subtilisin-family serine protease with reported activity across multiple proteolytic and cardiovascular targets, including SARS-CoV-2 spike protein, fibrinaloid amyloid microclots, fibrin clots, classical amyloid substrates, coagulation pathways, blood pressure, and carotid atherosclerotic plaque. Spike protein can persist in human tissues and circulation after infection and mRNA vaccination and has amyloidogenic properties capable of converting fibrinogen into fibrinolysis-resistant amyloid microclots. Human pharmacokinetic data demonstrate systemic exposure after oral NK dosing, with peak serum immunoreactivity at approximately 13 hours. Three independent laboratories have reported proteolytic degradation of spike by natto-derived or related alkaline serine proteases. Whole natto extract degraded recombinant receptor-binding domain and abolished viral infectivity in cultured cells; purified NK degraded full-length spike, the S2 subunit, and cell-surface spike in a dose- and time-dependent manner; and an unrelated alkaline serine protease independently reproduced spike degradation. Recombinant NK also degrades fibrinaloid microclots in vitro, while classical amyloid substrates susceptible to NK include Aβ40, Aβ42, human prion peptide fibrils, insulin fibrils, and β2-microglobulin fibrils. Fibrinolysis remains NK’s best-established biological activity. NK directly cleaves fibrin independently of plasminogen, inactivates plasminogen activator inhibitor-1, promotes tissue plasminogen activator release, and inhibits platelet aggregation and thrombus formation. Oral administration produces measurable systemic pharmacodynamic effects in humans, including changes in D-dimer, fibrin degradation products, factor VIII, antithrombin, activated partial thromboplastin time, fibrinogen, factor VII, and von Willebrand factor. Randomized evidence also supports modest blood-pressure reduction. Carotid imaging studies show no significant plaque effect at 2,000 or 3,600 FU/day, whereas 6,000 and 10,800 FU/day were associated with approximately 36% plaque reduction, suggesting a possible threshold near 6,000 FU/day. Higher natto intake is also associated with lower cardiovascular and stroke mortality. Overall, NK is a multi-target proteolytic agent with established fibrinolytic activity and convergent preclinical evidence against spike and amyloid substrates. The principal unresolved question is whether orally administered NK reaches these targets at catalytically sufficient concentrations in humans to produce measurable clinical benefit.

Zitieren

APA

Hulscher, N., Risch, H., MD, PhD, Thorp, J. A., MD, Pinsky, D., MD, Gillooly, P., MSc, Victory, K., MD, McCullough, P. A., MD, & MPH (2026). Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction. Medical Research Archives. https://doi.org/10.18103/mra.2026.0765

Vancouver

Hulscher N, Risch H, MD, PhD, Thorp JA, MD, et al. Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction. Medical Research Archives. 2026. doi:10.18103/mra.2026.0765

BibTeX
@article{Hulscher2026,
  author = {Hulscher, Nicolas and Risch, Harvey and MD and PhD and Thorp, James A. and MD and Pinsky, Drew and MD and Gillooly, Peter and MSc and Victory, Kelly and MD and McCullough, Peter A. and MD and MPH},
  title = {Proteolytic Targets and Clinical Benefits of Oral Nattokinase: Spike Protein and Amyloid Degradation, Fibrinolysis, and Cardiovascular Risk Reduction},
  journal = {Medical Research Archives},
  year = {2026},
  doi = {10.18103/mra.2026.0765}
}
Kostenlos starten →